The most striking effect of increased survival and improved quality of life in HIV-infected women undergoing antiretroviral therapy is the feasibility of motherhood-desire satisfaction. However, such advantages are often associated with drug-related metabolic toxicities, particularly relevant in the pregnancy context. Recent guidelines provide recommendations and trends for the use of antiretroviral therapy in pregnant women, but current literature falls short of providing specific insights on the need for metabolic monitoring and treatment in HIV-infected pregnant women. In this review we provide specific insight into the state-of-the-art of: detection, evaluation, and management of metabolic alterations in this special population. Pregnancy is in fact a metabolic transition process, potentially associated with specific diseases in the mother, in the newborn, and in the adulthood of the child. We will not simply discuss antiretroviral therapy metabolic toxicities, but rather their interaction with the physiological metabolic changes occurring during pregnancy. Close monitoring is needed to diagnose metabolic alterations that can lead to adverse outcomes in the mother, in the newborn, and potentially in adulthood. Lifestyle interventions and an appropriate metabolic tailoring of antiretroviral therapy drugs need to be considered in the prevention and treatment of metabolic alteration during pregnancy.

Metabolic alterations in HIV-infected pregnant women: moving to metabolic tailoring of antiretroviral drugs / Guaraldi, Giovanni; Stentarelli, Chiara; A. D., Da Silva; K., Luzi; Neri, Isabella; M., Cellini; E., Petrella; E., Garlassi; Menozzi, Marianna; Facchinetti, Fabio; Mussini, Cristina. - In: AIDS REVIEWS. - ISSN 1139-6121. - STAMPA. - 16:1(2014), pp. 14-22.

Metabolic alterations in HIV-infected pregnant women: moving to metabolic tailoring of antiretroviral drugs.

GUARALDI, Giovanni;STENTARELLI, Chiara;NERI, Isabella;Menozzi, Marianna;FACCHINETTI, Fabio;MUSSINI, Cristina
2014

Abstract

The most striking effect of increased survival and improved quality of life in HIV-infected women undergoing antiretroviral therapy is the feasibility of motherhood-desire satisfaction. However, such advantages are often associated with drug-related metabolic toxicities, particularly relevant in the pregnancy context. Recent guidelines provide recommendations and trends for the use of antiretroviral therapy in pregnant women, but current literature falls short of providing specific insights on the need for metabolic monitoring and treatment in HIV-infected pregnant women. In this review we provide specific insight into the state-of-the-art of: detection, evaluation, and management of metabolic alterations in this special population. Pregnancy is in fact a metabolic transition process, potentially associated with specific diseases in the mother, in the newborn, and in the adulthood of the child. We will not simply discuss antiretroviral therapy metabolic toxicities, but rather their interaction with the physiological metabolic changes occurring during pregnancy. Close monitoring is needed to diagnose metabolic alterations that can lead to adverse outcomes in the mother, in the newborn, and potentially in adulthood. Lifestyle interventions and an appropriate metabolic tailoring of antiretroviral therapy drugs need to be considered in the prevention and treatment of metabolic alteration during pregnancy.
2014
16
1
14
22
Metabolic alterations in HIV-infected pregnant women: moving to metabolic tailoring of antiretroviral drugs / Guaraldi, Giovanni; Stentarelli, Chiara; A. D., Da Silva; K., Luzi; Neri, Isabella; M., Cellini; E., Petrella; E., Garlassi; Menozzi, Marianna; Facchinetti, Fabio; Mussini, Cristina. - In: AIDS REVIEWS. - ISSN 1139-6121. - STAMPA. - 16:1(2014), pp. 14-22.
Guaraldi, Giovanni; Stentarelli, Chiara; A. D., Da Silva; K., Luzi; Neri, Isabella; M., Cellini; E., Petrella; E., Garlassi; Menozzi, Marianna; Facchinetti, Fabio; Mussini, Cristina
File in questo prodotto:
File Dimensione Formato  
hiv.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 237.41 kB
Formato Adobe PDF
237.41 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1017724
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact